Here's the recent articles submitted by srishti khurana
Articles By srishti khurana
The Contract Manufacturing Market For Live Biotherapeutics And Microbiome Products Is Estimated To B
Submitted as: Roots Analysis
Manufacturing live biotherapeutic product is both technically challenging and financially demanding; as a result, innovator firms are becoming increasingly reliant on contract service providers to access specialized facilities and optimize overall costs.(read
entire article)
View : 188 Times
Category : Business
The Microbiome Therapies Pipeline Features 260 Drugs Under Evaluation Across Different Phases Of Dev
Submitted as: Roots Analysis
Manufacturing live biotherapeutic products is both technically challenging and financially demanding; as a result, innovator firms are becoming increasingly reliant on contract service providers to access specialized facilities and optimize overall costs.(read
entire article)
View : 199 Times
Category : Business
The “live Biotherapeutic Products And Microbiome Contract Manufacturing Market: Focus On Active Phar
Submitted as: Roots Analysis
A detailed review of the overall landscape of companies offering contract services for manufacturing of microbiome therapeutics, including information on year of establishment, company size, scale of operation(read
entire article)
View : 198 Times
Category : Business
The Bispecific Antibody Therapeutics Market Is Estimated To Be Worth Usd 6.9 Billion In 2030, Predic
Submitted as: Roots Analysis
Bispecific antibody therapeutics represent a transformative approach to modern treatment; over the years, this upcoming class of ‘two-target' artificially engineered drugs have generated significant enthusiasm within the medical science community(read
entire article)
View : 97 Times
Category : Business
The Bispecific Antibody Therapeutics Market Is Projected To Grow At An Annualized Rate Of ~16%, In T
Submitted as: Roots Analysis
Roots Analysis has done a detailed study on Bispecific Antibody Therapeutics Market (4th Edition), 2020-2030, covering key aspects of the industry's evolution and identifying potential future growth opportunities.(read
entire article)
View : 102 Times
Category : Business
With Two Approved Drugs And Close To 300 Clinical / Preclinical Product Candidates, The Bispecific
Submitted as: Roots Analysis
With various target combinations and novel mechanisms of action, bispecific antibodies are presently recognized as a potent class of targeted therapies, with the potential to be used as treatment options for a variety of disease indications. Several pipeline candidates have recently entered mid to late-stage (phase II and above) trials and are anticipated to enter the market over the next 5-10 years.(read
entire article)
View : 99 Times
Category : General
The “bispecific Antibody Therapeutics Market (4th Edition), 2019-2030” Report Features An Extensive
Submitted as: Roots Analysis
A detailed review of the overall landscape of bispecific antibody therapeutics, including information on drug developers, phase of development (marketed, clinical, and preclinical / discovery) of the pipeline candidates, target antigen, type of antibody format, mechanism of action, target disease indication(s), therapeutic area, broader disease segment, route of administration, mode of administration and patient segment.(read
entire article)
View : 100 Times
Category : Business
The Gene Therapy Market Is Projected To Grow At An Annualized Rate Of 45%, Till 2030
Submitted as: Roots Analysis
Roots Analysis has done a detailed study on Gene Therapy Market (3rd Edition), 2019-2030, covering key aspects of the industry's evolution and identifying potential future growth opportunities.(read
entire article)
View : 96 Times
Category : Business
Presently, There Are More Than 10 Approved Gene Therapies; Over 465 Product Candidates Are Being Eva
Submitted as: Roots Analysis
Encouraging clinical results across various metabolic, hematological and ophthalmic disorders have inspired research groups across the world to focus their efforts on the development of novel gene editing therapies. In fact, the gene therapy pipeline has evolved significantly over the past few years, with three products being approved in 2019 alone; namely Beperminogene perplasmid (AnGes), ZOLGENSMA® (AveXis) and ZYNTEGLO™ (bluebird bio). Further, there are multiple pipeline candidates in mid to late-stage (phase II and above) trials that are anticipated to enter the market over the next 5-10 years.(read
entire article)
View : 100 Times
Category : Business
The “gene Therapy Market (3rd Edition), 2019-2030” Report Features An Extensive Study Of The Current
Submitted as: Roots Analysis
A detailed review of the overall landscape of gene therapies and genome editing therapies, including information on various drug / therapy developer companies, phase of development(read
entire article)
View : 95 Times
Category : Business
